Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
暂无分享,去创建一个
Leah Fitzgerald | Lin Chang | Jean Stains | Steven M Berman | M. Mandelkern | S. Derbyshire | S. Berman | B. Naliboff | E. Mayer | B. Suyenobu | J. Stains | Lin Chang | Bruce D Naliboff | Brandall Suyenobu | Emeran A Mayer | Mark Mandelkern | Stuart W Derbyshire | Lynn Hamm | Brent Vogt | L. Fitzgerald | B. Vogt | L. Hamm | Lynn R. Hamm
[1] B. Olivier,et al. 5-HT3 receptor antagonists and anxiety; a preclinical and clinical review , 2000, European Neuropsychopharmacology.
[2] E A Mayer,et al. Basic and clinical aspects of visceral hyperalgesia. , 1994, Gastroenterology.
[3] A. Randich,et al. Vagal modulation of nociception , 1992 .
[4] Gert Holstege,et al. Chapter 1 The emotional motor system , 1996 .
[5] C. Saper,et al. The biological basis for mind body interactions , 2000 .
[6] J. Galmiche,et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects , 1994, Alimentary pharmacology & therapeutics.
[7] A. Mangel,et al. Review article: evaluation of drugs in experimental gut distension models , 1999, Alimentary pharmacology & therapeutics.
[8] M. Hamon. Central and peripheral 5-HT3 receptors , 1992 .
[9] J. R. Augustine. Circuitry and functional aspects of the insular lobe in primates including humans , 1996, Brain Research Reviews.
[10] R Nieuwenhuys,et al. The greater limbic system, the emotional motor system and the brain. , 1996, Progress in brain research.
[11] J. Price,et al. Brain mediation of active and passive emotional coping. , 2000, Progress in brain research.
[12] Ronald Dubner,et al. Ratio scales of sensory and affective verbal pain descriptors , 1978, Pain.
[13] Gavin Kilpatrick,et al. Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. , 1989, European journal of pharmacology.
[14] Stuart W. G. Derbyshire,et al. Meta-Analysis of thirty-four independent samples studied using PET reveals a significantly attenuated central response to noxious stimulation in clinical pain patients , 1999, Current review of pain.
[15] B. Naliboff,et al. Stress and the gastrointestinal tract. V. Stress and irritable bowel syndrome , 2001 .
[16] M. Camilleri,et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.
[17] L. Derogatis,et al. The SCL-90-R, Brief Symptom Inventory, and Matching Clinical Rating Scales. , 1999 .
[18] M. Posner,et al. Cognitive and emotional influences in anterior cingulate cortex , 2000, Trends in Cognitive Sciences.
[19] M. Zhuo,et al. Characterization of descending facilitation and inhibition of spinal nociceptive transmission from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. , 1992, Journal of neurophysiology.
[20] E A Mayer,et al. Emerging disease model for functional gastrointestinal disorders. , 1999, The American journal of medicine.
[21] S. Derbyshire,et al. Cerebral Activation in Patients With Irritable Bowel Syndrome and Control Subjects During Rectosigmoid Stimulation , 2001, Psychosomatic medicine.
[22] M. Urban,et al. Supraspinal contributions to hyperalgesia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[23] B. K. Hartman,et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds , 1998, Pain.
[24] J. Le Bas,et al. Central processing of rectal pain in IBS patients: An fMRI study , 2000 .
[25] Karl J. Friston,et al. The Trouble with Cognitive Subtraction , 1996, NeuroImage.
[26] H. Vijverberg,et al. 5-HT3 receptors and neurotransmitter release in the CNS: a nerve ending story? , 2000, Trends in Neurosciences.
[27] D. Drossman,et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist , 1999, Alimentary pharmacology & therapeutics.
[28] M. E. Nevins,et al. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? , 1994, The Journal of pharmacology and experimental therapeutics.
[29] M. Delvaux,et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome , 1998, Alimentary pharmacology & therapeutics.
[30] Karl J. Friston,et al. Statistical parametric maps in functional imaging: A general linear approach , 1994 .
[31] L. Cubeddu,et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. , 1990, The New England journal of medicine.
[32] I. Tracey,et al. Cortical Processing of Human Somatic and Visceral Sensation , 1999, The Journal of Neuroscience.
[33] P. Jhingran,et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.
[34] R. Kessler,et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. , 2000, Gastroenterology.
[35] B. Vogt,et al. Contributions of anterior cingulate cortex to behaviour. , 1995, Brain : a journal of neurology.
[36] M. Mandelkern,et al. Gender differences in regional brain response to visceral pressure in IBS patients , 2000, European journal of pain.
[37] M. Gershon. Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.
[38] L. Johnson,et al. Physiology of the gastrointestinal tract , 2012 .
[39] I. Yamaguchi,et al. A mechanism of 5-HT3 receptor mediation is involved etiologically in the psychological stress lesion the stomach of the mouse. , 1994, The Journal of pharmacology and experimental therapeutics.
[40] E A Mayer,et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. , 1997, Gastroenterology.
[41] S. Caras,et al. Cilansetron shows efficacy in non-constipated irrirable bowel syndrome patients independent of the definition of the patient population by Rome I or Rome II , 2001 .